


Status: Currently Official on 15-Feb-2025  
Official Date: Official as of 01-May-2020  
Document Type: USP Monographs  
DocId: GUID-2267E40D-67E1-4CA7-AFD7-F25F5B71739C\_3\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M5212\\_03\\_01](https://doi.org/10.31003/USPNF_M5212_03_01)  
DOI Ref: 6gane

© 2025 USPC  
Do not distribute

## Metaxalone



$C_{12}H_{15}NO_3$  221.25

2-Oxazolidinone, 5-[(3,5-dimethylphenoxy)methyl]-;  
5-[(3,5-Xylyloxy)methyl]-2-oxazolidinone;  
5-[(3,5-Dimethylphenoxy)methyl]-1,3-oxazolidin-2-one CAS RN®: 1665-48-1; UNII: 1NMA9J598Y.

### DEFINITION

Metaxalone contains NLT 98.0% and NMT 102.0% of metaxalone ( $C_{12}H_{15}NO_3$ ), calculated on dried basis.

### IDENTIFICATION

**Change to read:**

- A. **▲SPECTROSCOPIC IDENTIFICATION TESTS (197), Infrared Spectroscopy: 197A or 197K▲** (CN 1-May-2020)

**Change to read:**

- B. The retention time of the major peak of the *Sample solution* corresponds to that of the **▲Standard solution,▲** (ERR 1-Apr-2019) as obtained in the Assay.

### ASSAY

#### • PROCEDURE

**Buffer:** 0.68 g/L of monobasic potassium phosphate in water. Adjust with phosphoric acid to a pH of 4.5.

**Mobile phase:** Methanol and *Buffer* (50:50)

**Standard stock solution:** 0.5 mg/mL of [USP Metaxalone RS](#) prepared as follows. Transfer a suitable quantity of [USP Metaxalone RS](#) to a suitable volumetric flask. Add 50% of the flask volume of methanol. Sonicate for 5 min to dissolve. Add 40% of the flask volume of *Buffer*, and mix. Cool to room temperature. Dilute with *Buffer* to volume.

**Standard solution:** 0.05 mg/mL of [USP Metaxalone RS](#) from the *Standard stock solution* in *Mobile phase*

**Sample stock solution:** 0.5 mg/mL of Metaxalone prepared as follows. Transfer a suitable quantity of Metaxalone to a suitable volumetric flask. Add 50% of the flask volume of methanol. Sonicate for 5 min to dissolve. Add 40% of the flask volume of *Buffer*, and mix. Cool to room temperature. Dilute with *Buffer* to volume.

**Sample solution:** 0.05 mg/mL of Metaxalone from the *Sample stock solution* in *Mobile phase*

#### Chromatographic system

(See [Chromatography \(621\), System Suitability.](#))

**Mode:** LC

**Detector:** UV 226 nm

**Column:** 4.6-mm × 15-cm; 5-μm packing L1

**Column temperature:** 50°

**Flow rate:** 1 mL/min

**Injection volume:** 20 μL

**Run time:** NLT 2 times the retention time of metaxalone

#### System suitability

**Sample:** *Standard solution*

#### Suitability requirements

**Tailing factor:** NMT 2.0

**Relative standard deviation:** NMT 0.73%

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of metaxalone ( $C_{12}H_{15}NO_3$ ) in the portion of Metaxalone taken:

$$\text{Result} = (r_u/r_s) \times (C_s/C_u) \times 100$$

$r_u$  = peak response from the *Sample solution*

$r_s$  = peak response from the *Standard solution*

$C_s$  = concentration of [USP Metaxalone RS](#) in the *Standard solution* (mg/mL)

$C_u$  = concentration of Metaxalone in the *Sample solution* (mg/mL)

**Acceptance criteria:** 98.0%–102.0% on the dried basis

## IMPURITIES

• [RESIDUE ON IGNITION \(281\)](#): NMT 0.30%

• **ORGANIC IMPURITIES, PROCEDURE 1**

If metaxalone related compound B, metaxalone related compound C, or N-benzyl metaxalone is a known process impurity, *Organic Impurities, Procedure 2* is recommended.

**Solution A:** 0.1% Trifluoroacetic acid in water

**Solution B:** 0.1% Trifluoroacetic acid in acetonitrile

**Mobile phase:** See [Table 1](#).

**Table 1**

Time (min)	Solution A (%)	Solution B (%)
0	75	25
10.0	65	35
11.0	75	25
15.0	75	25

**Diluent:** Acetonitrile and water (75:25)

**System suitability solution:** 4 mg/mL of [USP Metaxalone RS](#) and 0.01 mg/mL of 3,5-dimethylphenol in *Diluent*

**Sensitivity solution:** 0.002 mg/mL of [USP Metaxalone RS](#) in *Diluent*

**Sample solution:** 4 mg/mL of Metaxalone in *Diluent*

### Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC

**Detector:** UV 273 nm

**Column:** 4.6-mm × 25-cm; 5-μm packing L68

**Flow rate:** 2.0 mL/min

**Injection volume:** 10 μL

### System suitability

**Samples:** System suitability solution and Sensitivity solution

[NOTE—See [Table 2](#) for the relative retention times.]

### Suitability requirements

**Resolution:** NLT 2.0 between metaxalone and 3,5-dimethylphenol, *System suitability solution*

**Signal-to-noise ratio:** NLT 10, *Sensitivity solution*

### Analysis

**Sample:** *Sample solution*

Calculate the percentage of each impurity in the portion of Metaxalone taken:

$$\text{Result} = (r_u/r_T) \times 100$$

$r_u$  = peak response of each impurity from the *Sample solution*

$r_T$  = sum of the peak responses of metaxalone and impurities from the *Sample solution*

**Acceptance criteria:** See [Table 2](#). Disregard any impurity peaks less than 0.03%.

**Table 2**

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Metaxalone	1.0	—
3,5-Dimethylphenol	1.1	0.05
Any individual unspecified impurity	—	0.05
Total impurities	—	0.50

• **ORGANIC IMPURITIES, PROCEDURE 2**

If metaxalone related compound B, metaxalone related compound C, or N-benzyl metaxalone is a known process impurity, *Organic Impurities, Procedure 2* is recommended. If the article complies with *Procedure 2*, the labeling indicates that it meets *Organic Impurities, Procedure 2*.

**Buffer, Mobile phase, and Standard stock solution:** Proceed as directed in the Assay.

**Standard solution:** 0.001 mg/mL of [USP Metaxalone RS](#) from the Standard stock solution in Mobile phase

**Impurity stock solution:** 0.2 mg/mL each of [USP Metaxalone Related Compound B RS](#) and [USP Metaxalone Related Compound C RS](#) in methanol. Sonicate to dissolve if necessary.

**Peak identification solution:** 1 mg/mL of [USP Metaxalone RS](#) and 0.02 mg/mL each of [USP Metaxalone Related Compound B RS](#) and [USP Metaxalone Related Compound C RS](#) prepared as follows. Transfer a suitable quantity of [USP Metaxalone RS](#) to a suitable volumetric flask. Add 50% of the flask volume of methanol, and sonicate to dissolve. Transfer suitable volumes of *Impurity stock solution* to the flask. Dilute with *Buffer* to volume.

**Sample solution:** 2.0 mg/mL of Metaxalone prepared as follows. Transfer a suitable quantity of Metaxalone to a suitable volumetric flask. Add 50% of the flask volume of methanol. Sonicate for 5 min to dissolve. Add 40% of the flask volume of *Buffer*, and mix. Cool to room temperature. Dilute with *Buffer* to volume.

**Chromatographic system**

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC

**Detector:** UV 226 nm

**Column:** 4.6-mm × 15-cm; 5-μm packing L1

**Column temperature:** 50°

**Flow rate:** 1 mL/min

**Injection volume:** 20 μL

**Run time:** NLT 8 times the retention time of metaxalone

**System suitability**

**Sample:** Standard solution

**Suitability requirements**

**Tailing factor:** NMT 2.0

**Relative standard deviation:** NMT 10.0%

**Signal-to-noise ratio:** NLT 25

**Analysis**

**Samples:** Standard solution and Sample solution

Use the *Peak identification solution* to identify the peaks.

Calculate the percentage of each impurity in the portion of Metaxalone taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (1/F) \times 100$$

$r_U$  = peak response of each impurity from the *Sample solution*

$r_S$  = peak response of metaxalone from the *Standard solution*

$C_S$  = concentration of [USP Metaxalone RS](#) in the *Standard solution* (mg/mL)

$C_U$  = concentration of Metaxalone in the *Sample solution* (mg/mL)

$F$  = relative response factor for the corresponding impurity (see [Table 3](#))

**Acceptance criteria:** See [Table 3](#). Disregard any impurity peaks less than 0.03%.

**Table 3**

Name	Relative Retention Time	Relative Response Factor	Acceptance Criteria, NMT (%)
Metaxalone related compound B	0.35	1.0	0.05
Metaxalone	1.0	—	—
Metaxalone related compound C	3.6	1.0	0.05
<i>N</i> -Benzylmetaxalone <sup>a</sup>	6.9	0.64	0.05
Any individual unspecified impurity	—	1.0	0.05
Total impurities	—	—	0.3

<sup>a</sup> 3-Benzyl-5-[(3,5-dimethylphenoxy)methyl]oxazolidin-2-one.

#### SPECIFIC TESTS

- [Loss on Drying \(731\)](#).

**Analysis:** Dry at 90° for 2 h.

**Acceptance criteria:** NMT 0.5%

#### ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tight containers.
- **LABELING:** The label states with which *Organic Impurities* procedure the article complies if *Organic Impurities, Procedure 1* is not used.
- [USP Reference Standards \(11\)](#)

[USP Metaxalone RS](#)

[USP Metaxalone Related Compound B RS](#)

1-Amino-3-(3,5-dimethylphenoxy)propan-2-ol.  
 $C_{11}H_{17}NO_2$  195.26

[USP Metaxalone Related Compound C RS](#)

Bis[2-hydroxy-3-(3,5-dimethylphenoxy)propyl]amine.  
 $C_{22}H_{31}NO_4$  373.49

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
METAXALONE	<a href="#">Documentary Standards Support</a>	SM42020 Small Molecules 4

**Chromatographic Database Information:** [Chromatographic Database](#)

#### Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 40(3)

**Current DocID: GUID-2267E40D-67E1-4CA7-AFD7-F25F5B71739C\_3\_en-US**

**DOI:** [https://doi.org/10.31003/USPNF\\_M5212\\_03\\_01](https://doi.org/10.31003/USPNF_M5212_03_01)

**DOI ref:** [e6ane](#)